Clinical and Prognostic Differences in Mild to Moderate COPD With and Without Emphysema

Chest. 2024 Oct 23:S0012-3692(24)05397-2. doi: 10.1016/j.chest.2024.10.020. Online ahead of print.

Abstract

Background: The clinical and prognostic characteristics of mild-to-moderate COPD with and without emphysema remain inadequately investigated.

Research question: Do the clinical and prognostic characteristics differ between mild- to-moderate COPD with and without emphysema?

Study design and methods: We obtained clinical data of 989 participants with mild-to-moderate COPD from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). They were categorized into 2 groups based on their baseline low-attention lung voxels with a density < -950 Hounsfield units of < 5% on CT scans: mild-to-moderate COPD with emphysema (EC) group and mild-to-moderate COPD without emphysema (NEC) group. Linear mixed-effects models were used to assess the differences in the decline of lung function, health-related quality of life, and quantitative CT indexes between these 2 groups. Zero-inflated negative binomial regressions were used to evaluate the rates of acute respiratory exacerbations between the groups.

Results: Among participants with mild-to-moderate COPD, 428 (43.3%) exhibited emphysema on CT scans. The annual decline in FEV1 was -56.1 mL/y for the EC group and -46.9 mL/y for the NEC group, with a nonsignificant between-group difference of 9.1 mL/ (95% CI, -24.0 to 5.7 mL/y). The rate of emphysema progression in the EC group was significantly lower than in the NEC group (-0.173%; 95% CI, -0.252 to -0.094). The EC group also showed a more pronounced annual increase in the St. George's Respiratory questionnaire score (0.9 points) compared with the NEC group. The EC group had a higher rate of acute respiratory exacerbations (0.36 per person-year) than the NEC group (0.25 per person-year), with a rate ratio of 1.42 (95% CI, 1.27-1.54).

Interpretation: The EC group did not have accelerated rates of decline in FEV1, but they experienced significantly worse health-related quality of life and a higher rate of acute respiratory exacerbations. The nonemphysema subtype demonstrated increased emphysema progression.

Clinical trial registration: ClinicalTrials.gov; No.: NCT0196934; URL: www.

Clinicaltrials: gov.

Keywords: COPD; emphysema; epidemiology; mild to moderate.